Clinical trials: Rituximab, completed
Chronic Lymphocytic Leukemia
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00275054
- Testing
- Fludarabine, Cyclophosphamide, Rituximab
- Where
- 91 sites in Austria, France and 1 more
- Volunteers
- 825 people
- Sponsor
- German CLL Study Group
Primary Central Nervous System Lymphoma (PCNSL)
Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.
To evaluate the safety and tolerability and determine the recommended phase 2/phase 3 dose of RAD regimen in PCNSL
- Trial name
- NCT04688151
- Testing
- Rituximab
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- National Health Research Institutes, Taiwan
Non-Hodgkin's Lymphoma
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
Primary Objective: Evaluate the clinical activity of the RT-PEPC combination regimen (rituximab, thalidomide, and prednisone, etoposide, procarbazine, cyclophosphamide) in patients with relapsed mantle cell lymphoma.
- Trial name
- NCT00151281
- Testing
- PEPC, Thalidomide, Rituximab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Weill Medical College of Cornell University
Lymphoma
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
The goal of this clinical research study is to learn if chemotherapy given with rituximab, followed by Ibritumomab tiuxetan (Zevalin), and then followed by rituximab can help to control lymphoma.
- Trial name
- NCT00290511
- Testing
- Fludarabine, Mitoxantrone, Rituximab
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Post-transplant Lymphoproliferative Disease, Transplant-Related Hematologic Malignancy
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
This is an open label, non-randomised, multicentre Phase I to determine the safety of tacrolimus-resistant autologous EBV-specific cytotoxic T-cells (EBV CTL) and compare their expansion/persistence with control EBV CTL in solid…
- Trial name
- ITREC (NCT03131934)
- Testing
- Autologous EBV-CTL transduced with vector SFG-CNA12, Autologous EBV-CTL transduced with control vector SFG-CNA8, Leucapheresis
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- University College, London
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma
This phase I trial is studying how well monoclonal antibody therapy with peripheral stem cell transplant works in treating patients with non-Hodgkin's lymphoma.
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma
- Trial name
- NCT00017381
- Testing
- rituximab, cyclophosphamide, filgrastim
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
ANCA-associated Vasculitis, Granulomatosis With Polyangiitis
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
The goal of this multicentre observational study is to compare the safety and effectiveness of rituximab biosimilars to the originator in Canadian patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis…
- Conditions
- ANCA-associated Vasculitis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis
- Trial name
- BRAVO (NCT05716334)
- Where
- 9 sites in Canada
- Volunteers
- 201 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Lymphoma
S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00041132
- Testing
- filgrastim, rituximab, cyclophosphamide
- Volunteers
- 56 people
- Sponsor
- SWOG Cancer Research Network
Follicular Lymphoma, Mantle Cell Lymphoma
Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma
The anti-CD20 monoclonal antibodies, rituximab (R) and obinutuzumab (G), are used as standard maintenance therapy every 2 months for 2 to 3 years in patients with follicular lymphoma (FL) or mantle cell lymphoma (MCL).
- Trial name
- VAXIMAB (NCT04918940)
- Testing
- Determination of COVID-19 vacciantion efficacy
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Henri Becquerel
Diffuse Large B Cell Lymphoma
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
This is a prospective single-arm, multi-center, phase II clinical trial to observe the efficacy and safety of R-CHOP (Rituximab-Cyclophosphamide, Epirubicin, Vincristine and Prednisone) combined with lenalidomide in the…
- Trial name
- NCT04214626
- Testing
- Rituximab, Lenalidomide, Cyclophosphamide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Rheumatoid Arthritis
Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis
This study will compare the plasma pharmacokinetic profile and the change in disease activity score in patients with active rheumatoid arthritis following treatment with two 1000 mg doses of DRL_RI or one of two sources of…
- Trial name
- NCT02296775
- Testing
- DRL_RI, Rituxan, MabThera
- Where
- 28 sites in India, Ukraine
- Volunteers
- 276 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in…
- Trial name
- NCT04436107
- Testing
- Zanubrutinib, Lenalidomide
- Where
- 10 sites in China
- Volunteers
- 66 people
- Sponsor
- BeiGene
Non-Hodgkin's Lymphoma
Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma
This study aims to assess the short term efficacy of a combination of rituximab and low-dose radiotherapy in patients with non-Hodgkin's lymphoma.
- Trial name
- NCT00147953
- Testing
- Rituximab, Total nodal irradiation
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Cologne
Lymphoproliferative Disorder
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, prednisone, and methylprednisolone use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00066469
- Testing
- rituximab, cyclophosphamide, methylprednisolone
- Where
- 78 sites in United States, Australia and 2 more
- Volunteers
- 55 people
- Sponsor
- Children's Oncology Group
Chronic Lymphocytic Leukemia
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
This is an open label, Phase I/II, dose escalation research study of an investigational product called lumiliximab, given with FDA (Food and Drug Administration) approved products fludarabine, cyclophosphamide, and rituximab…
- Trial name
- NCT00103558
- Testing
- Lumiliximab with FCR
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Biogen
Waldenstrom's Macroglobulinemia
Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
This is a prospective, multicenter phase II trial designed to determine efficacy and safety of Bortezomib plus Rituximab plus Bendamustine in patients with relapsed/refractory Waldenstrom's Macroglobulinemia.
- Trial name
- FIL_BRB (NCT02371148)
- Testing
- Bortezomib-Rituximab-Bendamustine
- Where
- 23 sites in Italy
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma…
- Conditions
- Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
- Trial name
- NCT01397825
- Testing
- Alisertib (MLN8237), Rituximab, Vincristine
- Where
- 25 sites in United States, Italy and 2 more
- Volunteers
- 45 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Diffuse Large B-Cell Lymphoma
Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Primary Objective: Participants Achieving an Objective Response Rate (Cheson 2007) Secondary Objectives: Progression Free Survival Overall Survival Response Duration
- Trial name
- NCT01470456
- Testing
- SAR3419, rituximab
- Where
- 13 sites in Austria, France and 1 more
- Volunteers
- 50 people
- Sponsor
- Sanofi
Indolent or Intermediate Grade B-cell Malignancy
Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies
The purpose of this study is to assess the feasibility of a 60 minute rapid infusion rituximab protocol in the institution's outpatient infusion center.
- Trial name
- NCT01206777
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Rheumatoid Arthritis
An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)
This observational study will assess the execution, efficacy and safety of treatment with MabThera in patients with rheumatoid arthritis.
- Trial name
- NCT01075477
- Testing
- rituximab [Mabthera/Rituxan]
- Where
- 8 sites in Finland
- Volunteers
- 151 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.